SARS-CoV-2疫苗接种与初发或原有ITP患者的研究
该研究分析VAERS中初发ITP病例、10中心原有ITP患者接种SARS-CoV-2疫苗的回顾性研究及PDSA和UK ITP支持协会调查。原有ITP患者中首次接种后19/117例、第二次接种后14/70例出现ITP加重,脾切除和≥5线治疗者风险最高。两种情况对治疗反应良好,建议对已知ITP患者尤其是脾切除和难治者主动监测。
要点
- SARS-CoV-2疫苗接种后初发ITP中位血小板3×10^9/L,约1周出现,多数对治疗有反应。
- 原有ITP患者接种后可能出现加重,脾切除和≥5线治疗者风险最高。
- 建议对已知ITP患者,尤其脾切除和难治者,接种后主动监测。
核心结论
- SARS-CoV-2疫苗接种后初发ITP或原有ITP加重均可发生,但两者对治疗反应良好。
- 建议对已知ITP患者,尤其脾切除和更难治者,进行主动监测。
研究设计与样本
- 分析4个数据源:VAERS初发ITP病例、10中心原有ITP成人接种SARS-CoV-2疫苗的回顾性研究、PDSA和UK ITP支持协会的调查。
主要发现
- 117例原有ITP患者中,首次接种后19例出现ITP加重,第二次接种后70例中14例加重;加重定义包括血小板计数下降≥50%、最低血小板<30×10^9/L且较基线下降>20%和/或使用救援治疗。
- PDSA 57例和UK 43例ITP患者调查中,既往脾切除与血小板减少加重相关。
关键数值与推荐
- ITP加重定义:血小板计数下降≥50%、最低血小板计数<30×10^9/L且较基线下降>20%和/或使用救援治疗。
临床怎么用
- 对已知ITP患者接种SARS-CoV-2疫苗后应主动监测,尤其脾切除和更难治者。
- 初发ITP或原有ITP加重对糖皮质激素、IVIG和/或血小板输注等治疗反应良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cases of de novo immune thrombocytopenia (ITP), including a fatality, following SARS-CoV-2 vaccination in previously healthy recipients led to studying its impact in preexisting ITP. In this study, 4 data sources were analyzed: the Vaccine Adverse Events Reporting System (VAERS) for cases of de novo ITP; a 10-center retrospective study of adults with preexisting ITP receiving SARS-CoV-2 vaccination; and surveys distributed by the Platelet Disorder Support Association (PDSA) and the United Kingdom (UK) ITP Support Association. Seventy-seven de novo ITP cases were identified in VAERS, presenting with median platelet count of 3 [1-9] ×109/L approximately 1 week postvaccination. Of 28 patients with available data, 26 responded to treatment with corticosteroids and/or intravenous immunoglobulin (IVIG), and/or platelet transfusions. Among 117 patients with preexisting ITP who received a SARS-CoV-2 vaccine, 19 experienced an ITP exacerbation (any of: ≥50% decline in platelet count, nadir platelet count <30 × 109/L with >20% decrease from baseline, and/or use of rescue therapy) following the first dose and 14 of 70 after a second dose. Splenectomized persons and those who received 5 or more prior lines of therapy were at highest risk of ITP exacerbation. Fifteen patients received and responded to rescue treatment. In surveys of both 57 PDSA and 43 UK patients with ITP, prior splenectomy was associated with worsened thrombocytopenia. ITP may worsen in preexisting ITP or be identified de novo post-SARS-CoV2 vaccination; both situations responded well to treatment. Proactive monitoring of patients with known ITP, especially those postsplenectomy and with more refractory disease, is indicated.
引用
- Lee EJ, Beltrami-Moreira M, Al-Samkari H, et al. SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood. 2022. PMID: 34587251. doi:10.1182/blood.2021013411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。